Author

Anirban Lahiry

Observed name: A Lahiry

Institution: Nestlé (Switzerland)

Observed institutions: MorphoSys (Germany), GlaxoSmithKline (India), Nestlé (Switzerland)

ORCID: 0009-0008-9191-0136

Observed ORCID: 0009-0008-9191-0136

OpenAlex ID: A5034930545

A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study

2020 · Etienne F. Dumont, Amanda J. Oliver, et al. · Antimicrobial Agents and Chemotherapy · 26

First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.

2021 · David Belada, Katerina Kopeckova, et al. · Journal of Clinical Oncology · 12

The Impact of Low-Lactose, High Galacto-Oligosaccharides Milk on Gut Microbiome and Plasma Metabolome in Healthy Adults: A Randomized, Double-Blind, Controlled Clinical Trial Complemented by Ex Vivo Experiments

2025 · Léa Siegwald, Anna Cherta-Murillo, et al. · Current Developments in Nutrition · 5

Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes

2024 · Odd Erik Johansen, Joel Neutel, et al. · Metabolites · 2

Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial

2023 · Odd Erik Johansen, Delphine Curti, et al. · Nutrients · 2

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

2020 · David Belada, Grzegorz S. Nowakowski, et al. · Blood · 2

Efficacy of a Ready-to-Feed Starter Liquid Infant Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Chinese Infants: Protocol for a Double Blind, Randomized Controlled Trial

2025 · Ying Wang, Caroline Ivanne Le Roy, et al. · JMIR Research Protocols · 1

First‐mind: a Phase Ib, Open‐label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‐chop in Patients With Newly Diagnosed Dlbcl

2021 · D Belada, K Kopeckova, et al. · Hematological Oncology

Works count: 8

Citation count: 49

H-index: 3

I10-index: 2